Ligand Pharmaceuticals (LGND), GSK's (GSK) promacta approved - Report

November 19, 2012 9:03 AM EST Send to a Friend
Get Alerts LGND Hot Sheet
Trade LGND Now!
Join SI Premium – FREE
Ligand Pharmaceuticals (NASDAQ: LGND), GSK's (NYSE: GSK) promacta approved for treatment of low blood platelet counts in HepC patients, Adam Feuerstein reports.


Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

FDA, Trader Talk

Add Your Comment